Mela Sciences pulls in funding to fuel reimbursement push for melanoma Dx device

Mela Sciences ($MELA), a New York melanoma diagnostic device company, has raised $27.3 million in new financing to help it win reimbursement and pursue more clinical testing for its MelaFind system, which has U.S. and EU approval to help dermatologists diagnose melanoma. As our sister publication FierceMedicalDevices reported, Mela's shares dropped below the $1 minimum share price a few weeks ago. To maintain its listing, Mela did a one-for-10 reverse stock split, and the new investor financing followed. More

Suggested Articles

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.

Philips looked back on 15 years of data from one of its telehealth-equipped intensive care units, where centralizing operations reduced mortality.

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.